Quality Control & Regulatory Enforcement: Drug Administration of Vietnam Fines Pharmedic VND 50 Million for Class 3 Quality Defect in Sodium Chloride 0.9% Eye Drops Failing Clarity Standards

Key Development

The Drug Administration of Vietnam (DAV) under the Ministry of Health has officially issued an administrative sanction decision against Pharmedic Pharmaceutical Medicinal Materials JSC (HNX: PMC) following documented quality non-compliance in the manufacturing of its Sodium Chloride 0.9% Ophthalmic Solution.

Specific Lot Details & Administrative Penalty Structure:

• Affected Commercial Lot: Sodium Chloride 0.9% Eye Drops Solution, Marketing Authorization Number (Registration No.): 893100060724, Batch Number: 10370725, Manufacturing Date: July 14, 2025, Expiration Date: January 14, 2028.

• Quality Standard Infraction: The product failed registered specifications for the “Clarity” parameter (visible particulate matter), with regulatory laboratory testing identifying visible suspended particulates under standardized illuminated optical inspection, categorizing the infraction as a Class 3 quality violation.

• Administrative Sanction: The DAV imposed a financial penalty of VND 50 million ($~2,000 USD) on Pharmedic (with legal representative Mr. Le Viet Hung responsible for execution). No supplementary penalties or additional remedial measures were imposed, as mandatory product recall protocols had been executed previously.

• Preceding Nationwide Recall: In May 2026, the DAV issued an official directive mandating the nationwide recall of the entire defective batch 10370725, ordering the manufacturer to cease commercial distribution, quarantine inventory, and audit hospital and retail supply lines.

Why It Matters

• Clinical Hazards of Particulate Matter in Ophthalmic Formulations: Ophthalmic preparations demand absolute sterility and optical clarity. The presence of insoluble foreign particulate matter introduced into the ocular cavity risks corneal abrasion, conjunctival irritation, secondary bacterial contamination, or foreign-body reactions, posing heightened risks for neonatal and pediatric demographics.

• Broad Population Exposure & Market Penetration: Pharmedic’s Sodium Chloride 0.9% solution is one of the most widely utilized baseline medical consumables in Vietnam, distributed across thousands of public hospitals, outpatient clinics, and community pharmacies for ocular irrigation and nasal hygiene.

• Strengthening Post-Market Quality Oversight: Post-recall administrative enforcement confirms the Ministry of Health’s zero-tolerance stance on sterile product non-compliance, ensuring pharmaceutical manufacturers maintain strict cleanroom filtration standards.

Healthcare Insight Analysis

From the perspective of Healthcare Insight, the DAV’s administrative penalty on Pharmedic illustrates Sterile Ophthalmic Quality Control & Particulate Contamination Management.

Manufacturing liquid ophthalmics presents three specific quality engineering imperatives:

1. Compliance with Pharmacopoeial Clarity Monographs (Vietnamese Pharmacopoeia V): Ophthalmic formulations must be completely free of visible particulate matter under defined illumination lux levels. Contamination typically arises from upstream membrane filter degradation, packaging polymer shedding (LDPE), or environmental particulate ingress during the Blow-Fill-Seal (BFS) or filling-capping cycle.

2. Class 3 Violation Classification Framework: In Vietnamese pharmaceutical regulations, Class 3 defects represent non-critical quality standard deviations that do not pose immediate life-threatening toxicities but violate formal compendial monographs. The VND 50 million fine aligns with statutory penalty scales under healthcare decree frameworks.

3. Automated Optical Inspection Adoption: High-volume, low-margin small-volume parenterals (SVP) require transitioning from manual statistical visual sampling to fully automated high-speed optical inspection systems to catch sub-visible and visible defects before batch release.

Market Implications

1. Cleanroom & Sterile Filtration Audits at Pharmedic: The enterprise will execute thorough root-cause analyses and recalibrate sterile filtration trains at its primary manufacturing site in District 12, Ho Chi Minh City.

2. Elevated Surveillance on Topical Saline Products: Municipal and provincial Drug Quality Testing Centers will expand random market sampling targeting sterile saline washes and OTC eye drops.

3. Maintaining Healthcare Consumer Diligence: Pharmacists and clinical providers will verify batch numbers and visual clarity prior to dispensing pediatric saline washes.

Regulatory Matrix: Pharmedic Ophthalmic Non-Compliance Case (August 2026)

Source: https://tuoitre.vn/cong-ty-san-xuat-thuoc-nho-mat-natri-clorid-09-khong-dat-do-trong-bi-xu-phat-100260825173153613.htm